Anota Akofu, MD
Endocrinology, Diabetes & Metabolism · Carrollton, GANPI 1215376140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,085 of the $1,512 with a category attached, or 71.8%. 7 manufacturers reported payments, led by Medtronic at 50.6% of the total. 2025 is the largest year on record at $1,022, more than ten times the $65 reported in 2021. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in GA, where the typical reported total is $2,873.
Across 24 payments — averaging $63.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$766
- Dexcom, Inc.$174
- Amgen$156
- Amryt Pharma Holdings Ltd$133
- Phathom Pharmaceuticals, Inc.$125
- Radius Health, Inc.$91
- plus $67 from 1 others
What the payments were for
- Grants$574%
- Travel & lodging$37024%
- Food & beverage$1,08572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $766 |
| Dexcom, Inc. | 3 | $174 |
| Amgen | 3 | $156 |
| Amryt Pharma Holdings Ltd | 1 | $133 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Radius Health, Inc. | 1 | $91 |
| Abbott | 3 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$296
- TEPEZZA$135
- MYCAPSSA$133
- VOQUEZNA$125
How this compares
$1,512 in reported general payments places this provider in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $44,288 |
| JardianceEmpagliflozin | 38 | $27,276 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $2,735 |
| Novolog FlexpenInsulin Aspart | 11 | $1,605 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 18 | $1,355 |
| Levothyroxine Sodium | 53 | $264 |
| Atorvastatin Calcium | 16 | $129 |
| Methimazole | 12 | $125 |
| Metformin Hcl ErMetformin Hcl | 23 | $70 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Carrollton
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.